30J.F IDEAYA BIOSCIENCE DL-01

Healthcare Biotechnology Frankfurt Exchange
28.23 EUR
Close of Nov 11, 2026
23.66 36.06
Market cap
EUR 2.73B
P/E
-
P/B
2.82x
ROE
-41.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 30J.F undervalued?

Graham number

The Graham number of IDEAYA BIOSCIENCE DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IDEAYA BIOSCIENCE DL-01 fundamental analysis

No fundamental analysis for IDEAYA BIOSCIENCE DL-01 yet.

IDEAYA BIOSCIENCE DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IDEAYA BIOSCIENCE DL-01

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant setting…

Full company profile